CancerDrs

Pancreatic Cancer clinical trials in Colorado

39 actively recruiting pancreatic cancer trials at 20 sites across Colorado.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 3 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting Academic/Other

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-8 months of chemotherapy. Usual care …

Sponsor: NRG Oncology
NCT ID: NCT06958328
Sites in Colorado:
  • Rocky Mountain Cancer Centers-Boulder — Boulder, Colorado
  • Rocky Mountain Cancer Centers-Penrose — Colorado Springs, Colorado
  • UCHealth Memorial Hospital Central — Colorado Springs, Colorado
  • Memorial Hospital North — Colorado Springs, Colorado
  • AdventHealth Porter — Denver, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

This phase III trial compares the effect of adding panitumumab to standard chemotherapy (with nanoliposomal Irinotecan, leucovorin, and 5-fluorouracil \[5-FU\] or irinotecan, leucovorin, and 5-FU or nab-paclitaxel and gemcitabine) versus s…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06998940
Sites in Colorado:
  • Penrose-Saint Francis Healthcare — Colorado Springs, Colorado
  • Rocky Mountain Cancer Centers-Penrose — Colorado Springs, Colorado
  • Saint Francis Cancer Center — Colorado Springs, Colorado
  • CommonSpirit Cancer Center Mercy — Durango, Colorado
  • Mercy Medical Center — Durango, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).

Sponsor: Incyte Corporation
NCT ID: NCT07522073
Sites in Colorado:
  • Investigative Site US071 — Denver, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

The study is a multi-center, open-label, randomized active controlled study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.

Sponsor: RenovoRx
NCT ID: NCT03257033
Sites in Colorado:
  • Rocky Mountain Cancer Centers — Denver, Colorado
  • Comprehensive Cancer Care and Research Institute of Colorado, CCCRIC — Englewood, Colorado
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04858334
Sites in Colorado:
  • Penrose-Saint Francis Healthcare — Colorado Springs, Colorado
  • Rocky Mountain Cancer Centers-Penrose — Colorado Springs, Colorado
  • AdventHealth Porter — Denver, Colorado
  • CommonSpirit Cancer Center Mercy — Durango, Colorado
  • Mercy Medical Center — Durango, Colorado
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations

This phase II study evaluates how well pemigatinib works for the treatment of adult patients with pancreatic cancer that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or has s…

Sponsor: Sameek Roychowdhury
NCT ID: NCT06906562
Sites in Colorado:
  • Ohio State University-Telemedicine — Aurora, Colorado
  • Ohio State University Telemedicine — Denver, Colorado
  • Ohio State University Telemedicine — Durango, Colorado
  • Ohio State University Telemedicine — Grand Junction, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…

Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Colorado:
  • Rocky Mountain Cancer Center — Denver, Colorado
  • Sarah Cannon Research Institute at HealthONE — Denver, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.

Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in Colorado:
  • University of Colorado Cancer Center — Aurora, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Network

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…

Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Colorado:
  • Children's Hospital Colorado — Aurora, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

The study treatment, BAY 3713372, is under development to treat MTAP (methylthioadenosine phosphorylase)-deleted solid tumors. It is thought to work by blocking the protein arginine N-methyltransferase 5 (PRMT5). This may kill the MTAP-del…

Sponsor: Bayer
NCT ID: NCT06914128
Sites in Colorado:
  • UCHealth Cancer Center - Anschutz Medical Campus - University of Colorado Cancer Center — Aurora, Colorado
  • Sarah Cannon Research Institute at HCA HealthONE Presbyterian St. Luke's — Denver, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specif…

Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT05732831
Sites in Colorado:
  • Grand Valley Oncology — Grand Junction, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the bo…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06428409
Sites in Colorado:
  • University of Colorado Anschutz Medical Campus ( Site 0299) — Aurora, Colorado
  • University of Colorado Anschutz Medical Campus ( Site 0325) — Aurora, Colorado
  • University of Colorado Anschutz Medical Campus ( Site 0326) — Aurora, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: * Does CP-383 slow or stop the growth of…

Sponsor: Tasca Therapeutics
NCT ID: NCT07030257
Sites in Colorado:
  • Sarah Cannon Research Institute at HealthONE — Denver, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)

This study will check how well a new medicine, Risvutatug rezetecan, (Ris-Rez, also known as GSK5764227) works, how safe it is and how the body handles it in participants all around the world with advanced inoperable or metastatic gastroin…

Sponsor: GlaxoSmithKline
NCT ID: NCT06885034
Sites in Colorado:
  • GSK Investigational Site — Aurora, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Spevatamig (PT886). Pa…

Sponsor: Phanes Therapeutics
NCT ID: NCT05482893
Sites in Colorado:
  • Sarah Cannon Research Institute (SCRI) — Denver, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

The main goal of this study is to evaluate the safety of BNT329 and to identify the best dose of BNT329. This will be done by measuring the number of side effects that participants experience and how severe they are. The second goal of thi…

Sponsor: BioNTech SE
NCT ID: NCT07186842
Sites in Colorado:
  • SCRI at HCA Health One — Denver, Colorado
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

Sponsor: Bristol-Myers Squibb
NCT ID: NCT05245500
Sites in Colorado:
  • Rocky Mountain Cancer Centers, LLP - Oncology — Lone Tree, Colorado
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The s…

Sponsor: Eli Lilly and Company
NCT ID: NCT06586515
Sites in Colorado:
  • Sarah Cannon Research Institute at HealthOne — Denver, Colorado
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called…

Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT06131840
Sites in Colorado:
  • University of Colorado Hospital - Anschutz Cancer Pavilion (ACP) — Aurora, Colorado
  • University of Colorado Hospital — Aurora, Colorado
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat adva…

Sponsor: AbbVie
NCT ID: NCT06084481
Sites in Colorado:
  • University of Colorado Cancer Center - Cancer Clinical Trials Office /ID# 255128 — Aurora, Colorado
  • Sarah Cannon Research Institute at HealthONE - Denver /ID# 258926 — Denver, Colorado
View on ClinicalTrials.gov →

Showing 25 of 39 trials with sites in Colorado. See all pancreatic cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-09-07